Notogen Inc is a San Diego-based biotechnology company specializing in the development of innovative treatments for back and neck dysfunction caused by spinal disc degeneration. Their lead product, NTG-101, is a patented protein-based formulation that offers a non-surgical and non-cellular approach to degenerative disc disease, promoting disc regeneration and alleviating discogenic pain without the risks associated with surgery or cell therapy.
With a focus on spinal regenerative medicine, Notogen is dedicated to providing effective solutions for conditions related to spinal pain and degeneration. Their NTG-101 drug candidate benefits from clearly defined regulatory and manufacturing pathways, making it a promising option for patients seeking a scalable and clinically viable treatment for degenerative disc disease.
Generated from the website